AOD9604 5MG

AOD9604 5MG

$72.00

AOD9604 is a modified hGH fragment developed as a fat-burning compound. It shows potential in heart disease treatment, cartilage repair, and metabolic syndrome management.

64 in stock (can be backordered)

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

AOD9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone (hGH), specifically amino acids 177-191, with an additional tyrosine residue at the N-terminus for stabilization. This 16-amino acid peptide was initially developed as a potential treatment for obesity, designed to mimic the lipolytic (fat-burning) properties of hGH without its growth-promoting or diabetogenic side effects. AOD9604 has shown promise in various applications, from weight management to tissue repair and regeneration, and has recently gained attention in the cosmetic industry for its potential to reduce cellulite and subcutaneous fat.

Sequence:Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Molecular Formula:C221H342N46O68

Molecular Weight:1815.07 g/mol

CAS Number:221231-10-3

  1. Weight Loss: In a 12-week randomized clinical trial, subjects receiving AOD9604 (1 mg/d) lost an average of 2.6 kg, compared to 0.8 kg in the placebo group. However, a subsequent 24-week trial with a larger cohort did not show significant weight loss effects.
  2. Cartilage Regeneration: Intra-articular AOD9604 injections using ultrasound guidance enhanced cartilage regeneration in a rabbit model of osteoarthritis. Combined AOD9604 and hyaluronic acid injections were more effective than either treatment alone.
  3. Safety Profile: Multiple non-clinical studies revealed no evidence of genotoxicological or toxicological concerns regarding the safety of AOD9604. It was found to be generally safe after chronic oral application in rats and cynomolgus monkeys.
  4. Metabolic Effects: AOD9604 does not stimulate the production of IGF-1, unlike full-length hGH, potentially reducing the risk of diabetes-related side effects.
  5. Cosmetic Applications: Recent research has explored AOD9604's potential as a cosmeceutical product for reducing cellulite and subcutaneous fat.

  1. Mechanism of Action: Further research is needed to fully elucidate the molecular mechanisms by which AOD9604 exerts its diverse effects, particularly in different tissue types.
  2. Optimal Delivery Methods: Investigation into various administration routes and formulations could enhance the therapeutic potential of AOD9604.
  3. Long-term Effects: Extended studies are required to evaluate the long-term effects and safety profile of AOD9604 in various applications.
  4. Combination Therapies: Exploring potential synergistic effects of AOD9604 with other therapeutic agents could open new avenues for treatment in various medical fields.
  5. Expanded Clinical Applications: Further investigation into AOD9604's potential benefits in conditions characterized by tissue damage or chronic inflammation is warranted.

  1. Stier, H., et al. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15. [Online].
    Available: https://jofem.org/index.php/jofem/article/view/157/194
  2. Cox, H. D., et al. (2015). Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis, 7(1), 31-38. [Online].
    Available: https://onlinelibrary.wiley.com/doi/pdf/10.1002/dta.1715
  3. SZieba, R., et al. (2014). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of Clinical & Laboratory Science, 45(4), 426-432. [Online].
    Available: http://www.annclinlabsci.org/content/45/4/426.full
  4. Valentino, M. A., et al. (2010). Obesity Pharmacotherapy: Current Perspectives and Future Directions. Clinical Pharmacology & Therapeutics, 87(6), 650-661. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584306/
  5. RegenX Health. (2023). The Journey of AOD-9604: From Clinical Trials to Cosmetic Triumphs. [Online].
    Available:https://www.regenxhealth.com/post/the-journey-of-aod-9604-from-clinical-trials-to-cosmetic-triumphs
  6. Stier, H., et al. (2018). Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism, 8(6), 107-116. [Online].
    Available: https://jofem.org/index.php/jofem/article/view/213/278
AOD9604 represents a promising avenue for various therapeutic and cosmetic applications, particularly in fat metabolism and tissue repair. As with all research peptides, it is important to use AOD9604 in controlled settings, and its potential benefits and risks require further scientific scrutiny before any clinical applications can be considered.